IMS Health (IMS) Tops Q4 EPS by 5c

IMS Health (NYSE: IMS) reported Q4 EPS of $0.37, $0.05 better than the analyst estimate of $0.32. Revenue for the quarter came in at $812 million versus the consensus estimate of $787.59 million.

2016 Full-Year Guidance

IMS Health expects constant currency results for full-year 2016 as follows: Revenue growth of 10 to 12 percent, Adjusted EBITDA growth of 7.5 to 9.5 percent, Adjusted Net Income growth of 6.5 to 8.5 percent and Adjusted Diluted Earnings per Share growth of 8.5 to 10.5 percent.

Assuming foreign exchange rates hold at current levels through the end of 2016, IMS Health expects reported revenue growth of 7.5 to 9.5 percent, Adjusted EBITDA growth of 6 to 8 percent, Adjusted Net Income growth of 0.5 to 2.5 percent and Adjusted Diluted Earnings per Share growth of 2.5 to 4.5 percent.

For earnings history and earnings-related data on IMS Health (IMS) click here.

You May Also Be Interested In

• Piper Sandler defends Oracle ahead of earnings, sees $2.2 billion OCI upside
• Lynx Equity on Lam Research (LRCX): 'Closing in on full valuation'
• Wall St opens higher as chip shares recover